Evidence map›Paper›PMID 33068293›Full record

Trial reportEuropean journal of clinical investigation2021

The value of high-flow nasal cannula oxygen therapy in treating novel coronavirus pneumonia.

Xiao-Bao Teng, Ya Shen, Ming-Feng Han, Gang Yang, Lei Zha, Jing-Feng Shi

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 6 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 6 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. High-flow nasal cannulaTherapeutic advances in respiratory disease
    Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Effectiveness of high-flow nasal cannula therapy on clinical outcomes in adults with COVID-19: A systematic review.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiao-Bao TengDepartment of Respiratory and Critical Care Medicine, No. 2 People's Hospital of Fuyang City, Fuyang, China.
Ya ShenDepartment of Respiratory and Critical Care Medicine, No. 2 People's Hospital of Fuyang City, Fuyang, China.
Ming-Feng HanDepartment of Respiratory and Critical Care Medicine, No. 2 People's Hospital of Fuyang City, Fuyang, China.ORCID https://orcid.org/0000-0001-8091-2285
Gang YangDepartment of Respiratory and Critical Care Medicine, No. 2 People's Hospital of Wuhu City, Wuhu Anhui, China.
Lei ZhaDepartment of Respiratory and Critical Care Medicine, No. 2 People's Hospital of Wuhu City, Wuhu Anhui, China.
Jing-Feng ShiDepartment of Respiratory and Critical Care Medicine, No. 2 People's Hospital of Fuyang City, Fuyang, China.
Fuyang City People's Hospital · CNWuhu No 1 People's Hospital · CN

Funding

The second batch of COVID-19 emergency science and technology project in Fuyang city FK20202802
6 · The paper itself

Abstract

objectiveThis study aimed to investigate the value of high-flow nasal cannula (HNFC) oxygen therapy in treating patients with severe novel coronavirus pneumonia (COVID-19).

methodsThe clinical data of 22 patients with severe COVID-19 were collected. The heart rate (HR), respiratory rate (RR) and oxygenation index (PO

resultsThe differences at 0 hours between the two groups were not statistically significant. Compared with COT group,in the HFNC oxygen therapy group, HR, RR and PaO

conclusionCompared with COT, early application of HFNC oxygen therapy in patients with severe COVID-19 can improve oxygenation and RR, and HFNC oxygen therapy can improve the infection indexes of patients and reduce the length of stay in the ICU of patients. Therefore, it has high clinical application value.

Indexed as

Blood Gas AnalysisCannulaCOVID-19C-Reactive ProteinFemaleHeart RateHumansIntensive Care UnitsLength of StayLeukocyte CountLymphocyte CountMaleMiddle AgedOxygenOxygen Inhalation TherapyPartial PressureC-Reactive ProteinOxygenProcalcitonincoronavirus disease 2019high nasal flow oxygen therapypneumonia

Identifiers

PMID33068293
PMCPMC7645937
OpenAlexW3092729981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.